Our results suggest the intestinal-selective PXR activation regulates B3galt5 expression and maintains metabolic homeostasis, making it a potential therapeutic strategy in obesity. This evidence concerns the gene B3GALT5 and obesity due to melanocortin 4 receptor deficiency.